Xenetic Biosciences, Inc. (NASDAQ:XBIO) posted its quarterly earnings results on Tuesday, May 16th. The company reported ($0.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.21) by $0.13, Bloomberg Earnings reports.
Xenetic Biosciences (NASDAQ XBIO) traded down 6.14% during mid-day trading on Friday, reaching $2.60. The company’s stock had a trading volume of 4,401 shares. Xenetic Biosciences has a 12-month low of $2.60 and a 12-month high of $37.62. The firm’s 50 day moving average is $3.40 and its 200-day moving average is $4.02. The company’s market cap is $22.66 million.
COPYRIGHT VIOLATION WARNING: This article was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://www.chaffeybreeze.com/2017/06/16/xenetic-biosciences-inc-xbio-posts-earnings-results-misses-estimates-by-0-13-eps-updated-updated-updated.html.
Separately, Zacks Investment Research raised Xenetic Biosciences from a “sell” rating to a “hold” rating in a report on Tuesday, May 30th.
Xenetic Biosciences Company Profile
Xenetic Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company’s platform technologies that enables the creation of drug therapies primarily for orphan indications.
Receive News & Ratings for Xenetic Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.